Literature DB >> 10853873

The use of fixed-mixture insulins in clinical practice.

H E Turner1, D R Matthews.   

Abstract

BACKGROUND: Pre-mixed insulins currently represent about 40% of the world market in human insulin. Despite the fact that many patients are being treated with these insulin formulations, there are surprisingly few data about fixed mixtures and comparisons with other administration schedules. The main advantages of using a pre-mixed preparation over a self-mixed insulin are increased accuracy of dosage, efficacy and patient convenience. These benefits may lead to increased compliance resulting in better long-term control of the disease. Insulin mixtures are used by a wide variety of patients with type-1 and type-2 diabetes. Pre-mixed insulins also appear to be useful in elderly and adolescent patients with diabetes, although there are few published data on patients in these groups.
CONCLUSIONS: It is likely that, in the future, fixed mixtures containing rapid-acting insulin analogues, such as insulin lispro, and possibly newly formulated intermediate-acting insulin analogues, such as neutral protamine lispro, may allow further improvements in both metabolic control and patient convenience.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853873     DOI: 10.1007/s002280050715

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

Review 1.  Starting insulin therapy in elderly patients.

Authors:  T J Hendra
Journal:  J R Soc Med       Date:  2002-09       Impact factor: 5.344

Review 2.  One hundred years of insulin therapy.

Authors:  Chantal Mathieu; Pieter-Jan Martens; Roman Vangoitsenhoven
Journal:  Nat Rev Endocrinol       Date:  2021-08-17       Impact factor: 43.330

3.  A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.

Authors:  J Gordon; R D Pockett; A P Tetlow; P McEwan; P D Home
Journal:  Int J Clin Pract       Date:  2010-10-04       Impact factor: 2.503

4.  EADSG Guidelines: Insulin Therapy in Diabetes.

Authors:  Bahendeka Silver; Kaushik Ramaiya; Swai Babu Andrew; Otieno Fredrick; Sarita Bajaj; Sanjay Kalra; Bavuma M Charlotte; Karigire Claudine; Anthony Makhoba
Journal:  Diabetes Ther       Date:  2018-03-05       Impact factor: 2.945

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.